IRVINE, Calif., Aug. 29, 2011 /PRNewswire/ — Masimo
(NASDAQ:
MASI) today announced the Japanese Ministry of Health Labor
& Welfare (MHLW) and Health Canada regulatory clearances of
Masimo Pronto-7™— enabling clinicians throughout Japan
and Canada to quickly and conveniently measure total hemoglobin
(SpHb®), SpO2, perfusion index, and pulse rate without removing
a drop of blood.
Hemoglobin is one of the most commonly ordered tests in both the
hospital and pre-hospital settings because it is critical to
assessing blood loss following trauma, during surgery, and during
hospital stay, as well as a patient’s need for a blood transfusion.
However, traditional lab testing requires a painful needle stick
for the patient, time-consuming blood draws for the clinician, and
typically provides delayed results. Masimo SpHb provides immediate
real-time hemoglobin results that enable clinicians to more rapidly
assess patients and detect and treat internal bleeding and low
hemoglobin conditions earlier. And, although Masimo
noninvasive and continuous total hemoglobin (SpHb)
monitoring—commercially available in both Japan and Canada
for over a year—is the preferred technology for hospitals and
inpatient care centers, access to quick and easy spot-check
hemoglobin measurements are valuable for a variety of healthcare
assessment applications, including physician offices, outpatient
care centers, and pre-hospital emergency settings.
Pronto-7 Makes Noninvasive Hemoglobin Testing a Reality in
Japan and Canada
Japanese and Canadian regulatory clearances for the palm-sized,
handheld Pronto-7 and noninvasive finger sensors make it possible
for clinicians to take the pain and wait out of traditional
hemoglobin blood testing. The Pronto-7 offers a breakthrough
solution for measuring tot
‘/>”/>
